Rheumatology

As Biosimilar Adalimumab Gains Ground in Europe, Ixekizumab Shows Superiority to Humira in PsA

July 2nd 2019

By Kelly Davio

Given the head-to-head data from the SPIRIT trial, Humira maker AbbVie may face even further challenges in trying to maintain its sales as newer products like ixekizumab advance in such therapeutic areas as psoriatic arthritis (PsA).

Switching to Biosimilar Rituximab, Truxima, Is Effective and Well Tolerated in Patients With RA

June 25th 2019

By Kelly Davio

Article

Recently, researchers reported 72-week results from a phase 3 trial of biosimilar rituximab, CT-P10 (Truxima), in patients with rheumatoid arthritis (RA), in which they concluded that the product was well tolerated in long-term use and that switching from the reference did not yield differences in safety, efficacy, pharmacodynamics, or immunogenicity.

Celltrion Presents More Data Showing Comparable Efficacy, Safety of Subcutaneous CT-P13 to IV Form

June 19th 2019

By Allison Inserro

Article

Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the European League Against Rheumatism European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).

Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds

June 17th 2019

By Kelly Davio

Article

A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with inflammatory diseases.

In the Short Term, Most Patients With RA Remain on a Biosimilar Post Switch

June 16th 2019

By The Center for Biosimilars Staff

Article

During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, researchers from the University of Manchester reported on their findings regarding patients with rheumatoid arthritis (RA) involved in the BSRBR-RA study who had switched from reference infliximab or reference etanercept to biosimilars.

In Early Study, Researchers Modify Infliximab to Make It Safer, More Effective

June 14th 2019

By The Center for Biosimilars Staff

Article

Researchers say they were able to create an “antibody lock” that makes infliximab more selective in its activity, making it safer and more effective.

Biosimilar Adalimumab, Hulio, Is Safe Long-Term, Causes Less Injection-Site Pain Than Humira

June 14th 2019

By Kelly Davio

Article

During this week’s European League Against Rheumatism Annual European Congress of Rheumatology, researchers will present on the long-term safety, immunogenicity, and efficacy of the biosimilar versus the reference in an open-label extension study that involved switching between the biosimilar and the reference.

Studies Disagree on the Role of Education, Nocebo Effect in Biosimilar Switching

June 13th 2019

By Kelly Davio

Article

During this week’s European League Against Rheumatism European Congress of Rheumatology 2019, 2 research teams will present their contrasting findings on education and the nocebo effect.

Real-World Data on SB4 Highlight Biosimilar Etanercept's Efficacy

June 12th 2019

By Kelly Davio

Article

During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, multiple teams of researchers will present their findings on real-world evidence of the biosimilar’s efficacy and the feasibility of switching to SB4 from the reference etanercept, Enbrel.

In the Changing Biosimilar Landscape, Canadian Rheumatology Association Updates Its Position

May 30th 2019

By Kelly Davio

Article

The Canadian Rheumatology Association (CRA) has issued an update to its position statement on biosimilars. In the document, the CRA says that evidence for the risk/benefit ratio for biosimilars is accruing rapidly, and physicians must demonstrate fiscal responsibility while providing the best care possible to individual patients.